PRAGUE MEDICAL REPORT, Vol 124 No 1 (2023), 33–39
Screening for SARS-COV-2 Using RT-qPCR in Patients with Hematologic Neoplasms Receiving Chemotherapy
Ignacio Martín Santarelli, Mariela Sierra, Sofía Isabel Fernández
DOI: https://doi.org/10.14712/23362936.2023.3
zveřejněno: 10. 02. 2023
Abstract
It has been recommended that patients with leukaemias and lymphomas undergo universal screening for SARS-COV-2 using RT-qPCR before each treatment on the grounds of their high risk of experiencing severe forms of COVID-19. This raises a conflict with different recommendations which prioritise testing symptomatic patients. We found that among 56 RT-qPCR obtained in asymptomatic patients with hematologic neoplasms before chemotherapy administration, 2 (3.5%) were positive. A negative result did not exclude SARS-COV-2 infection in 1 patient (1.8%). It is unclear what the benefit of screening for SARS-COV-2 using RT-qPCR in patients with hematologic neoplasms who receive chemotherapy is.
klíčová slova: Hematologic neoplasms; Chemotherapy; COVID-19 testing; Asymptomatic disease
Screening for SARS-COV-2 Using RT-qPCR in Patients with Hematologic Neoplasms Receiving Chemotherapy is licensed under a Creative Commons Attribution 4.0 International License.
167 x 240 mm
vychází: 4 x ročně
cena tištěného čísla: 450 Kč
ISSN: 1214-6994
E-ISSN: 2336-2936
